Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-04-30-30-30-30
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$110.96 million
Profitability
Miscellaneous
Employees195
Next Earnings Date6/19/2019 (Estimated)
OptionableNot Optionable
Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions
What is Innate Pharma's stock symbol?
Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF."
When is Innate Pharma's next earnings date?
What is the consensus analysts' recommendation for Innate Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innate Pharma.
Has Innate Pharma been receiving favorable news coverage?
News articles about IPHYF stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include Endo International (ENDP), Innoviva (INVA), Cambrex (CBM), Esperion Therapeutics (ESPR), Heron Therapeutics (HRTX), Gossamer Bio (GOSS), Opko Health (OPK), Aimmune Therapeutics (AIMT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Apellis Pharmaceuticals (APLS), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Epizyme (EPZM) and Inflarx (IFRX).
What other stocks do shareholders of Innate Pharma own?
Who are Innate Pharma's key executives?
Innate Pharma's management team includes the folowing people:
- Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)
- Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)
- Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)
- Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)
- Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55)
How do I buy shares of Innate Pharma?
Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innate Pharma's stock price today?
One share of IPHYF stock can currently be purchased for approximately $6.39.
How big of a company is Innate Pharma?
Innate Pharma has a market capitalization of $368.06 million and generates $110.96 million in revenue each year. The company earns $3.60 million in net income (profit) each year or $0.06 on an earnings per share basis. Innate Pharma employs 195 workers across the globe.
What is Innate Pharma's official website?
How can I contact Innate Pharma?
Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-04-30-30-30-30 or via email at [email protected]
MarketBeat Community Rating for Innate Pharma (OTCMKTS IPHYF)
MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe IPHYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
